Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119122 | 0.88 | AR (0.33) | ARHDAC3HDAC4HDAC6DYRK1A | |
| SCHEMBL3650563 | 0.87 | CTSD (0.33) | CTSDBACE1BACE2 | |
| SCHEMBL4125110 | 0.87 | AR (0.32) | ARDYRK1A | |
| SCHEMBL3650568 | 0.86 | CTSD (0.32) | CTSDBACE1BACE2 | |
| SCHEMBL4130796 | 0.85 | MGAM (0.36) | ARHDAC3HDAC4HDAC6DYRK1A | |
| SCHEMBL4119012 | 0.85 | LIPG (0.32) | DYRK1A | |
| SCHEMBL3799051 | 0.84 | ALDH1A1 (0.35) | ARHDAC3HDAC4HDAC6DYRK1A | |
| SCHEMBL3652323 | 0.84 | L3MBTL1 (0.31) | HDAC3HDAC4HDAC6DYRK1A | |
| SCHEMBL4132219 | 0.83 | DYRK1A (0.33) | ARDYRK1A | |
| SCHEMBL4120659 | 0.83 | EDNRA (0.38) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | CTSD 264/4885BACE1 1566/4885BACE2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.